Discovery of a potent and selective human AC2 inhibitor based on 7-deazapurine analogues of adefovir

Bioorg Med Chem. 2023 Nov 15:95:117508. doi: 10.1016/j.bmc.2023.117508. Epub 2023 Oct 26.

Abstract

Adefovir based acyclic nucleoside phosphonates were previously shown to modulate bacterial and, to a certain extent, human adenylate cyclases (mACs). In this work, a series of 24 novel 7-substituted 7-deazaadefovir analogues were synthesized in the form of prodrugs. Twelve analogues were single-digit micromolar inhibitors of Bordetella pertussis adenylate cyclase toxin with no cytotoxicity to J774A.1 macrophages. In HEK293 cell-based assays, compound 14 was identified as a potent (IC50 = 4.45 μM), non-toxic, and selective mAC2 inhibitor (vs. mAC1 and mAC5). Such a compound represents a valuable addition to a limited number of small-molecule probes to study the biological functions of individual endogenous mAC isoforms.

Keywords: 7-Deazapurine; Acyclic nucleoside phosphonates; Adefovir; Adenylate cyclase; Prodrugs.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenylate Cyclase Toxin
  • Adenylyl Cyclases*
  • HEK293 Cells
  • Humans
  • Nucleosides / chemistry
  • Organophosphonates* / pharmacology

Substances

  • 7-deazapurine
  • adefovir
  • Adenylate Cyclase Toxin
  • Adenylyl Cyclases
  • Organophosphonates
  • Nucleosides